Aquestive Therapeutics Inc (AQST) concluded trading on Thursday at a closing price of $4.09, with 2.84 million shares of worth about $11.62 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 192.14% during that period and on April 11, 2024 the price saw a gain of about 0.49%. Currently the company’s common shares owned by public are about 89.97M shares, out of which, 76.25M shares are available for trading.
Stock saw a price change of -1.68% in past 5 days and over the past one month there was a price change of -19.80%. Year-to-date (YTD), AQST shares are showing a performance of 102.48% which increased to 268.47% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.10 but also hit the highest price of $6.23 during that period. The average intraday trading volume for Aquestive Therapeutics Inc shares is 2.25 million. The stock is currently trading -9.75% below its 20-day simple moving average (SMA20), while that difference is up 7.77% for SMA50 and it goes to 76.30% higher than SMA200.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Aquestive Therapeutics Inc (NASDAQ: AQST) currently have 89.97M outstanding shares and institutions hold larger chunk of about 26.45% of that.
The stock has a current market capitalization of $367.98M and its 3Y-monthly beta is at 2.91. It has posted earnings per share of -$0.14 in the same period. It has Quick Ratio of 1.87. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for AQST, volatility over the week remained 5.99% while standing at 8.43% over the month.
Stock’s fiscal year EPS is expected to drop by -185.58% while it is estimated to increase by 14.19% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Piper Sandler on Apr-12-24 offering an Overweight rating for the stock and assigned a target price of $10 to it. Coverage by Raymond James stated Aquestive Therapeutics Inc (AQST) stock as an Outperform in their note to investors on March 28, 2024, suggesting a price target of $7 for the stock. Stock get a Buy rating from Lake Street on January 03, 2019.
